Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01301001
Other study ID # 10-00985-FB CSBrown Vulvodynia
Secondary ID
Status Completed
Phase N/A
First received May 13, 2010
Last updated November 6, 2017
Start date August 2012
Est. completion date January 2016

Study information

Verified date April 2016
Source University of Tennessee
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Specific aims of this project are to (1) test the prediction that pain from tampon insertion (primary outcome measure) is lower in PVD patients when treated with gabapentin compared to when treated with placebo. Secondary outcome measures include intercourse pain and 24-hour pain and (2)perform a mechanism-based analysis of gabapentin effectiveness, and to gain insight into the underlying pathophysiology of subtypes of PVD that may lead to more specific treatment options.


Description:

This is a 18-week, randomized, double-blind, placebo-controlled, two-treatment, two-period crossover design, where 120 women between 18 of age and older who report insertional dyspareunia, pain with tampon insertion, and tenderness localized to the vulvar vestibule will be enrolled in the study. Electronically entered daily diaries will be used to determine if pain is lower in PVD subjects when treated with gabapentin (up to 3600 mg/d) compared to when treated with placebo. Biological measurements will include assessment of allodynia and hyperalgesia from capsaicin administration, muscle tension using a vaginal pressure algometer, number of tender points by clinical examination, and changes in blood pressure, pulse and heart rate variability. . The Long-range goals of this project are to explicate the underlying pathophysiologic mechanisms of PVD, and to use this knowledge to create evidence-based differential diagnoses of subtypes of PVD and to individualize treatments for each subtype. The immediate goal is to conduct a multicenter, randomized controlled trial (RCT) of gabapentin treatment for PVD, and which will also provide critical data on a new PVD-testing and response paradigm, as well as on characteristics that may define subtypes of PVD. Gabapentin, an anticonvulsant with analgesic, anxiolytic, and antispasmotic effects, was selected because of its efficacy in treating other neuropathic pain conditions.


Recruitment information / eligibility

Status Completed
Enrollment 230
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Women who are 18 years of age and older, as long as no vaginal atrophy is present. If vaginal atrophy is present, then topical hormone replacement can be provided for a minimum of 6 weeks and then she must be re-screened to be eligible,

2. Greater than 3 continuous months of insertional (entryway) dyspareunia, pain to touch, or both with tampon insertion (modified 'Friedrich's Criteria', and

3. an average pain level of "4" or greater on the 11-point tampon test (0 = no pain at all; 10 = worse pain ever) during the 2-week screening period must be exhibited.

(One tampon will be inserted each week). 4.) Must report pain with the "Tampon Insertion Pain" Test at visit 1

Exclusion Criteria:

1. Other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, or atrophic vaginitis (presence of a maturation index)

2. previous vestibulotomy

3. active vaginal infection (positive Affirm ™ VPIII microbial identification test)

4. pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study

5. any unstable medical condition, including renal impairment (creatinine clearance of =60 mL/min, BUN > 30mg/dL, serum creatinine > 2 mg/dL), significant hematological disease (leukopenia [WBC < 3.0 x 10-3µl, leukocytosis [WBC >20.0 x 10-3µl], neutropenia [ABS < 1.50 x 10-3 µl, <20%]), (thrombocytopenia [platelets < 100,000 µl], anemia [HCT < 27%, HBG <8 g/dL, RBC <3 x 10-6]), cardiovascular disease (cardiac conduction disturbance, CHF, hypertension [140/90]), hepatic insufficiency (serum AST, ALT, or ALP = 3 times upper limit of normal), neurological disorder (seizures, syncopal episodes, peripheral neuropathy, severe pain other than that caused by vulvodynia), autoimmune disease, or respiratory illness

6. psychiatric disorder, including history of major depressive disorder or substance abuse disorder within the past 6 months, a score of > 12 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS), indicting a major depressive episode (35,36), a serious risk of suicide, or lifetime history of psychosis, hypomania or mania

7. multiple allergies

8. use of benzodiazepines, opiates, muscle relaxants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or CNS stimulants (including methylphenidate, amphetamine dextroamphetamine) within 2 weeks of randomization and during the study

9. use of certain herbal agents within 2 weeks of randomization and during the study, including ginkgo biloba, evening primrose, St. John's Wort, Valerian, kava kava)

10. topical lidocaine use

11. Subjects, who are diagnosed with coexisting vaginismus, fibromyalgia and/or interstitial cystitis, must have greater vulvar pain than their coexisting conditions or they will not be eligible for study participation

12. Subject who have previously taken gabapentin or Lyrica but discontinued the medication due to side effects are not eligible

13. Subjects with active infections (Candida, BV, trichomonas, chlamydia, GC and HSV via Affirm/culture) must be treated and re-screened to eligible for participation

14. Subjects with 10% or greater parabasal cells and/or vaginal atrophy can be provided with topical hormone replacement for a minimum of 6 weeks and then must be re-screened to be eligible

15. Subjects who have had gastric bypass surgery are ineligible for study participation due to drug absorption problems

16. HPV/abnormal Pap is not exclusionary

17. Ongoing counseling and/or physical therapy is not exclusionary

18. Subjects who report signs of mixed Vulvodynia (spontaneous/provoked, localized, generalized) during prescreening will not be excluded

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo oral capsule
Placebo 2 capsules am and 3 capsules pm
Gabapentin
Gabapentin 1200 mg am and 1800 mg pm

Locations

Country Name City State
United States Clinical Research Center Memphis Tennessee
United States Rutgers - Robert Wood Johnson Medical School New Brunswick New Jersey
United States University of Rochester School of Medicine and Dentistry Rochester New York

Sponsors (2)

Lead Sponsor Collaborator
University of Tennessee University of Tennessee Health Science Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tampon Test Pain Intensity Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days). Week 6 for each treatment arm
Secondary Coital Pain Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm. Week 6 of each treatment arm
Secondary Vulvodynia Pain Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged. Week 6 for each treatment arm
See also
  Status Clinical Trial Phase
Completed NCT05478746 - Effects of Flourish HEC on Localized Provoked Vulvodynia N/A
Completed NCT02404961 - Women's Health Study: Immunological Factors and Risk of Vulvodynia
Completed NCT00751010 - Relationship: Interstitial Cystitis & Vulvodynia-Part 2 N/A
Completed NCT00607490 - A Randomized Clinical Trial for Women With Vulvodynia N/A
Recruiting NCT03640624 - Multidisciplinary Treatment of Chronic Vulvar Pain N/A
Recruiting NCT05343182 - Vestibulectomy Surgical Techniques Comparison Study N/A
Recruiting NCT05518630 - An Investigation of Nomothetic Versus Idiographic Assessment in Chronic Pain
Recruiting NCT05597358 - Efficacy of High Intensity Laser for Provoked Vestibulodynia N/A
Completed NCT01304589 - Savella in Treatment for Provoked Vestibulodynia Phase 3
Completed NCT00590590 - Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort Phase 2
Recruiting NCT06138171 - Personality, Defences, Central Sensitization, and Trauma in Women With Chronic Migraine, Fibromyalgia, and Vulvodynia
Completed NCT01996384 - Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study Phase 1
Completed NCT01664962 - Search for Genetic Basis of Vulvodynia N/A
Recruiting NCT05955313 - Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia Phase 2
Completed NCT02773641 - Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia Phase 3
Completed NCT00501774 - A Search for Helicobacter Pylori in Localized Vulvodynia N/A
Completed NCT04057755 - Botulinum Toxin A as a Treatment for Provoked Vestibulodynia Phase 3
Terminated NCT04016467 - Effect of Spinal Manipulation on Vulvar Pain N/A
Completed NCT01935063 - Study to Compare the Efficacy of Cognitive-behavioral Couple Therapy and Lidocaine for Provoked Vestibulodynia N/A
Completed NCT02809612 - An Internet-based Information Platform for Vulvodynia Patients N/A